As chief commercial officer and chief operating officer he led the transformation of the company's global commercial organization into one uniquely designed to be able to differentially invest in the most important opportunities. He helped build the company's leadership in immuno-oncology through his roles in U.S. Through ever-expanding roles, Caforio has made significant contributions to improving the company's strategic focus and operational performance. "With Giovanni's appointment as CEO and Lamberto's appointment as chairman, we ensure the continuation of both the leadership and strategy that have made BMS successful."Ĭaforio brings a broad range of experience to his role as CEO. "This is an extraordinary company of talented people with incomparable passion and dedication to helping patients," Cornelius said. I look forward to working with our very talented team of people at BMS to build on what we've accomplished, to deliver on the promise of our innovative portfolio and to continue to make a real difference for our patients." "Lamberto has led the successful transformation of BMS from a broad-based health care company to a Diversified Specialty BioPharma leader with his passion for our business, our people and, most importantly, our patients. "I am honored to have the privilege to lead this great company," Caforio said. From his start in a medical role to his experience as a general manager to his roles as chief commercial officer and chief operating officer, Giovanni has demonstrated a unique ability to work across the organization to bring innovative medicines to patients." He has an unmatched breadth and depth of experience. "I have a high level of confidence in Giovanni that is shared by everyone who has seen him consistently and successfully drive performance. "I also want to express my excitement that Giovanni has been appointed to succeed me as CEO," Andreotti said. As CEO of Bristol-Myers Squibb, I am grateful to have had his guidance as a mentor and a friend." "Through his leadership and strategic vision, Jim oversaw the successful transformation of our company. "I want to thank Jim Cornelius for his many years at BMS," Andreotti said. West, Jr., 72, will become the lead independent director on the company's board. Cornelius, 71, has chosen not to stand for re-election as non-executive chairman and will retire from the board.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |